

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

THE RESULTS OF THREE PRECLINICAL STUDIES WILL BE PRESENTED AT THE AACR 2023

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Company will present the results of three preclinical studies of KRAS^{multi} inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting 2023 (the “**AACR 2023**”) from April 14 to 19, 2023.

About the Abstract:

Abstract Number: 1660

Title: Preclinical investigation of orally bioavailable, potent KRAS^{multi} inhibitor JAB-23425

KRAS^{multi} inhibitor JAB-23425 targets multiple KRAS mutants in both RAS(ON) and RAS (OFF), with good selectivity over HRAS and NRAS. JAB-23425 has significant antitumor effect on cancer models with multiple KRAS mutations (such as G12D, G12V, and G13D) and amplification of wild type KRAS, and has no inhibitory effect on KRAS-independent cells. The KRAS^{multi} inhibitor JAB-23425 is expected to solve the unmet clinical needs of patients with KRAS-mutated tumors. JAB-23425 is a leading compound of the Company’s KRAS^{multi} inhibitor series.

Abstract Number: 6606

Title: JAB-X1800: a potent immunostimulatory antibody-drug conjugate (iADC) targeting CD73

JAB-X1800 is the world’s first iADC by conjugating the Company’s STING agonist to CD73 antibody, which is expected to turn the tumor from “cold” to “hot”, and combine synergize with anti-PD-1 mAb.

Abstract Number: 1645

Title: JAB-2485: a potent, highly selective small-molecule Aurora kinase A inhibitor that targets cell division

JAB-2485 is one of the top two highly selective Aurora A inhibitor with 1500-fold selectivity over Aurora kinase B and Aurora kinase C, with high activity and low bone marrow toxicity as well as favorable PK properties.

Please visit the official website of AACR 2023 for more information:

<https://www.aacr.org/meeting/aacr-annual-meeting-2023/>

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market KRAS^{multi} inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, March 14, 2023

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Daqing CAI and Dr. Ge WU as independent non-executive Directors.